Simplex Trading’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3,373
| Closed | -$6K | – | 10411 |
|
|
2023
Q1 | $6K | Sell |
3,373
-3,591
| -52% | -$4.45K | ﹤0.01% | 7989 |
|
|
2022
Q4 | $7K | Sell |
6,964
-4,004
| -37% | -$5.7K | ﹤0.01% | 7889 |
|
|
2022
Q3 | $25K | Buy |
+10,968
| New | +$38.8K | ﹤0.01% | 7301 |
|
|
2022
Q2 | – | Sell |
-287
| Closed | -$1.4K | – | 11533 |
|
|
2022
Q1 | $1K | Buy |
+287
| New | +$2.05K | ﹤0.01% | 10216 |
|
|
2021
Q1 | – | Sell |
-2,166
| Closed | -$23.7K | – | 10385 |
|
|
2020
Q4 | $15K | Sell |
2,166
-1,827
| -46% | -$14.2K | ﹤0.01% | 7176 |
|
|
2020
Q3 | $32K | Buy |
+3,993
| New | +$24.8K | ﹤0.01% | 6026 |
|
|
2020
Q1 | – | Sell |
-24,027
| Closed | -$138K | – | 8490 |
|
|
2019
Q4 | $209K | Buy |
+24,027
| New | +$130K | ﹤0.01% | 3706 |
|
|
2019
Q3 | – | Sell |
-234
| Closed | -$937 | – | 8089 |
|
|
2019
Q2 | $1K | Buy |
+234
| New | +$1.24K | ﹤0.01% | 6940 |
|
|
2019
Q1 | – | Sell |
-137
| Closed | -$662 | – | 8097 |
|
|
2018
Q4 | $0 | Sell |
137
-54,404
| -100% | -$254K | ﹤0.01% | 8066 |
|
|
2018
Q3 | $354K | Buy |
54,541
+28,013
| +106% | +$208K | ﹤0.01% | 2982 |
|
|
2018
Q2 | $203K | Buy |
26,528
+22,754
| +603% | +$328K | ﹤0.01% | 3470 |
|
|
2018
Q1 | $84K | Buy |
3,774
+1,029
| +37% | +$22.8K | ﹤0.01% | 1950 |
|
|
2017
Q4 | $34K | Buy |
+2,745
| New | +$40.4K | ﹤0.01% | 2809 |
|
Other funds holding JNCE
Simplex Trading's JNCE Position: Q2 2023 in Review
Simplex Trading sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 3,373 shares — an estimated $6K sold.
Simplex Trading first reported a position in JNCE in Q4 2017 and held it in 13 quarters. The position peaked at $354K in Q3 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Simplex Trading reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Simplex Trading sold 3,373 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $6K.
- Simplex Trading first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 13 quarters.
- Simplex Trading's Jounce Therapeutics, Inc. Common Stock position peaked at $354K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.